Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in Phase 3 Study of ELGN-2112 for Treatment of Intestinal Malabsorption in Preterm Infants
Chiesi Group delivers on transformational strategy with FY2024 double-digit growth (13% at CER), strong investment in innovation and continued focus on sustainability
16 Aprile 2025
Chiesi Acquires New Manufacturing Site in Nerviano (Milan) with a Strategic €430 Million Investment To 2030 to Drive Global Growth
26 Marzo 2025
Chiesi Group appoints three new independent Non-Executive Directors to its Board, supporting company evolution and growth
29 Gennaio 2025
Great Place To Work and Fortune Name Chiesi Group No. 23 in 2024 World’s Best Workplaces™ List
14 Novembre 2024
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
30 Settembre 2024
Chiesi Group Unveils Innovations in Respiratory Care, Patient Insights into Decentralization of a Clinical Trial and Developments in Carbon Minimal Inhaler Project at ERS Congress 2024
03 Settembre 2024
Bringing Sustainability and Strategy together to create Shared Value: Insights from Chiesi’s 2023 Sustainability Report
22 Luglio 2024
Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants
